(CMPS) – StreetInsider.com Reports
-
Morgan Stanley Starts Compass Pathways (CMPS) at Overweight, 'current valuation provides an attractive entry point ahead of a catalyst rich year'
-
COMPASS Pathways (CMPS) Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
-
COMPASS Pathways plc (CMPS) enters into research collaboration agreement with Hackensack Meridian Health
-
COMPASS Pathways plc (CMPS) and Greenbrook TMS (GBNH) Enter Three-year Research Collaboration Agreement
-
COMPASS Pathways plc (CMPS) Reports COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder
-
Deutsche Bank Starts Compass Pathways (CMPS) at Buy
-
COMPASS Pathways (CMPS) appoints Teri Loxam as Chief Financial Officer
-
COMPASS Pathways (CMPS) announces study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry
-
Compass Pathways (CMPS) PT Lowered to $38 at BTIG
-
COMPASS Pathways plc (CMPS) Misses Q3 EPS by 15c
-
COMPASS Pathways (CMPS) announces CFO transition
-
COMPASS Pathways (CMPS) Appoints Daphne Karydas to its Board
-
COMPASS Pathways plc (CMPS) Announces 40.90M Share Offering by Selling Stockholders
-
Compass Pathways (CMPS) PT Lowered to $50 at Canaccord Genuity
-
COMPASS Pathways plc (CMPS) Announces $285M Private Placement at $7.78/sh
-
COMPASS Pathways (CMPS) Report Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360
-
COMPASS Pathways plc (CMPS) Tops Q1 EPS by 12c
-
Citi Maintains Compass Pathways (CMPS) at Buy, Lowers PT
-
Compass Pathways (CMPS) PT Lowered to $22 at Evercore ISI
-
COMPASS Pathways plc (CMPS) Misses Q4 EPS by 11c
-
EF Hutton Starts Compass Pathways (CMPS) at Buy
-
Compass Pathways (CMPS) PT Lowered to $33 at Oppenheimer
-
Berenberg Resumes Compass Pathways (CMPS) at Buy
-
COMPASS Pathways plc (CMPS) Reports Publication of Phase 2b Study of COMP360 Psilocybin Therapy
-
UPDATE: Loop Capital Starts Compass Pathways (CMPS) at Buy
-
Compass Pathways (CMPS) PT Lowered to $60 at Canaccord Genuity
-
Compass Pathways (CMPS) PT Lowered to $55 at Oppenheimer
-
Compass Pathways (CMPS) PT Lowered to $46 at Citi
-
COMPASS Pathways plc (CMPS) Tops Q2 EPS by 11c
-
COMPASS Pathways plc (CMPS) Appoints Kabir Nath as CEO
-
Increasing unusual option volume: CMPS PTEN KDP ILMN
-
Compass Pathways (CMPS) PT Lowered to $78 at Canaccord Genuity
-
COMPASS Pathways plc (CMPS) Selected for Addition to NASDAQ Biotechnology Index
-
COMPASS Pathways plc (CMPS) Announces Executive Team Changes
-
COMPASS Pathways plc (CMPS) Reports Positive Outcome of 25mg COMP360 Psilocybin Therapy as Adjunct to SSRI Antidepressants
-
COMPASS Pathways plc (CMPS) Appoints Michael Falvey as CFO
-
COMPASS Pathways plc (CMPS) Granted Fifth US Patent for Crystalline Psilocybin
-
Increasing unusual put option volume: CMPS MQ EVGO ONON SEAH BHC
-
Compass Pathways (CMPS) PT Raised to $65 at Oppenheimer, Following Earnings
-
Increasing unusual put option volume: CMPS PRTY EVGO LAZR VIRT
-
Compass Pathways (CMPS) PT Raised to $117 at Roth Capital
-
COMPASS Pathways plc (CMPS) Reports Positive Topline Results from Phase IIb trial of COMP360 psilocybin therapy
-
Oppenheimer Starts Compass Pathways (CMPS) at Outperform
-
COMPASS Pathways plc (CMPS) Topline Data of COMP360 Psilocybin Therapy for Cancer Patients Shows Feasibility of Simultaneous Psilocybin Administration in Small Groups
-
COMPASS Pathways plc (CMPS) Granted New US Crystalline Psilocybin Patent
-
Increasing unusual put option volume: JNK CMPS VST TTM EWH MILE GOGO
-
COMPASS Pathways plc (CMPS) Acquires Portfolio of Novel Psychedelic Compounds and Prodrugs
-
Citi Starts Compass Pathways (CMPS) at Buy
-
UPDATE: Maxim Group Starts Compass Pathways (CMPS) at Buy
-
BTIG Starts Compass Pathways (CMPS) at Buy
Back to CMPS Stock Lookup
